Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
- 1 July 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (1) , 355-357
- https://doi.org/10.1182/blood.v96.1.355
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Selection and transplantation of autologous CD34+ B‐lineage negative cells in advanced‐phase multiple myeloma patients: a pilot studyBritish Journal of Haematology, 1999
- Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case reportBone Marrow Transplantation, 1999
- Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic CellsJournal of Clinical Oncology, 1999
- Graft-versus-myelomaBone Marrow Transplantation, 1998
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myelomaBone Marrow Transplantation, 1998
- A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumorsLeukemia, 1997
- Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.Journal of Clinical Oncology, 1995
- Allogeneic Bone Marrow Transplantation in Multiple MyelomaNew England Journal of Medicine, 1991
- Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and stagingBritish Journal of Haematology, 1982